공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

두경부 편평상피세포암 : 파이프라인 리뷰

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 11월 상품 코드 251612
페이지 정보 영문 722 Pages
가격
US $ 2,000 ₩ 2,260,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,521,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,781,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


두경부 편평상피세포암 : 파이프라인 리뷰 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016
발행일 : 2016년 11월 페이지 정보 : 영문 722 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

두경부 편평상피세포암은 두경부(비강, 부비동내, 입술, 입, 침샘, 인후, 후두)에서 발생하는 암이며, 목의 지속성 통증, 삼킴 장애와 통증, 지속적인 쉰 목소리, 목소리 변화, 귀의 통증, 입 안이나 목에서의 출혈 등의 증상이 있습니다. 치료 방법에는 화학요법, 방사선 치료가 있습니다.

세계의 두경부 편평상피세포암(Head And Neck Cancer Squamous Cell Carcinoma) 치료제 파이프라인에 대해 조사 분석했으며, 현재의 개발 파이프라인 상황과 최신 동향, 치료제 개요, 주요 기업 및 개발중인 제품 리뷰 등의 정보를 전해드립니다.

서론

  • 조사 범위

두경부 편평상피세포암 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

두경부 편평상피세포암 : 기업에서 개발중인 치료제

두경부 편평상피세포암 : 대학/기관에서 연구중인 치료제

두경부 편평상피세포암 : 파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품
  • 개발 단계가 불명인 제품

두경부 편평상피세포암 : 기업에서 개발중인 제품

두경부 편평상피세포암 : 대학/기관에서 연구중인 제품

두경부 편평상피세포암 치료제 개발에 참여하고 있는 기업

  • AB Science SA
  • AbbVie Inc.
  • Acceleron Pharma, Inc.
  • Advaxis, Inc.
  • Altor BioScience Corporation
  • Amgen Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • Bayer AG
  • Bionovis SA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • CEL-SCI Corporation
  • Cellceutix Corporation
  • Celldex Therapeutics, Inc.
  • Celltrion, Inc.
  • Centrose LLC
  • Critical Outcome Technologies Inc.
  • Daiichi Sankyo Company, Limited
  • Debiopharm International SA
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Etubics Corporation
  • F. Hoffmann-La Roche Ltd.
  • G&E Herbal Biotechnology Co., Ltd.
  • Genexine, Inc.
  • Genmab A/S
  • GlaxoSmithKline Plc
  • Gliknik, Inc.
  • Glycotope GmbH
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Horizon Pharma Plc
  • Immunomedics, Inc.
  • Immunovative Therapies, Ltd.
  • Incyte Corporation
  • Innate Pharma S.A.
  • Inovio Pharmaceuticals, Inc.
  • IRX Therapeutics, Inc.
  • Kolltan Pharmaceuticals, Inc.
  • Laboratoires Pierre Fabre SA
  • Loxo Oncology, Inc.
  • Mabion SA
  • MacroGenics, Inc.
  • Marsala Biotech Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Merck KGaA
  • Merrimack Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Mirati Therapeutics Inc.
  • Molecular Partners AG
  • Molplex Ltd.
  • Novartis AG
  • Oncobiologics, Inc.
  • Oncolytics Biotech Inc.
  • Onconova Therapeutics, Inc.
  • OncoSec Medical Incorporated
  • Ono Pharmaceutical Co., Ltd.
  • OXiGENE, Inc.
  • Panacea Biotec Limited
  • PCI Biotech Holding ASA
  • Pfizer Inc.
  • Sanofi
  • Shanghai Henlius Biotech Co., Ltd.
  • Shenzen SiBiono GeneTech Co., Ltd.
  • Shionogi & Co., Ltd.
  • Sillajen Biotherapeutics
  • Symphogen A/S
  • Synta Pharmaceuticals Corp.
  • Takara Bio Inc.
  • Threshold Pharmaceuticals, Inc.
  • UbiVac, LLC
  • VasGene Therapeutics, Inc.
  • VentiRx Pharmaceuticals, Inc.
  • Virttu Biologics Limited
  • Viventia Bio Inc.
  • Vyriad

두경부 편평상피세포암 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품(Combination Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개요

두경부 편평상피세포암 : 최근의 파이프라인 동향

두경부 편평상피세포암 : 휴지중인 프로젝트

두경부 편평상피세포암 : 개발이 중지된 제품

두경부 편평상피세포암 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSM 16.06.20

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016, provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline landscape.

Head and Neck Cancer Squamous Cell Carcinoma is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx. The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 49, 49, 2, 23, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 4 and 2 molecules, respectively.Head And Neck Cancer Squamous Cell Carcinoma.

Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Head And Neck Cancer Squamous Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Head And Neck Cancer Squamous Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Head And Neck Cancer Squamous Cell Carcinoma Overview
  • Therapeutics Development
  • Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies
  • Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance
  • Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies
  • Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes
  • Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development
  • Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment
  • Drug Profiles
  • Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects
  • Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products
  • Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2016
  • Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AB Science SA, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AbbVie Inc, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Accelerated Pharma, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Advaxis, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Altor BioScience Corporation, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AstraZeneca Plc, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bayer AG, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bionovis SA, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by BioNTech AG, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Calithera Biosciences, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by CEL-SCI Corporation, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Centrose LLC, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Critical Outcome Technologies Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by CytImmune Sciences, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eleven Biotherapeutics Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Etubics Corporation, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by GeneSegues Inc, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genexine, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genmab A/S, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Gliknik, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Glycotope GmbH, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Horizon Pharma Plc, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunomedics, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunovative Therapies, Ltd., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Incyte Corporation, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Innate Pharma S.A., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by IRX Therapeutics, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Johnson & Johnson, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Laboratoires Pierre Fabre SA, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Loxo Oncology, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mabion SA, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MacroGenics, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Marsala Biotech Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mateon Therapeutics Inc, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune LLC, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck KGaA, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mirati Therapeutics Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molecular Partners AG, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molplex Ltd., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by NanoCarrier Co., Ltd., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OncoSec Medical Incorporated, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech Holding ASA, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Pfizer Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sanofi, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Symphogen A/S, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by SynCore Biotechnology Co., Ltd., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Takara Bio Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Transgene SA, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by UbiVac, LLC, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VasGene Therapeutics, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Virttu Biologics Limited, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Vyriad Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..1), H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..2), H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..3), H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..4), H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H2 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2016
  • Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top
전화 문의
F A Q